H.C. Wainwright analyst Arthur He downgraded BioAtla (BCAB) to Neutral from Buy without a price target The firm is awaiting clarity on the company’s pipeline development path. The firm says that with pipeline decisions pending, it is unable to project the cadence of BioAtla’s revenue at this time.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks